Publicacions recents

  1. Genetic architecture of neurodegenerative dementias. Clarimon, J, Moreno-Grau, S, Cervera-Carles, L et al. Neuropharmacology 2020
    PMID:32097768

  2. Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. Cantero, JL, Atienza, M, Lage, C et al. Cereb. Cortex 2019
    PMID:31799623

  3. APP-derived peptides reflect neurodegeneration in frontotemporal dementia. Illán-Gala, I, Pegueroles, J, Montal, V et al. Ann Clin Transl Neurol 2019
    PMID:31789459

  4. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alcolea, D, Clarimón, J, Carmona-Iragui, M et al. Alzheimers Dement (N Y) 2019
    PMID:31650016

  5. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Alcolea, D, Pegueroles, J, Muñoz, L et al. Ann Clin Transl Neurol 2019
    PMID:31464088

  6. Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. Carmona-Iragui, M, Videla, L, Lleó, A et al. Dev Neurobiol 2019
    PMID:31278851

  7. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. Morenas-Rodríguez, E, Alcolea, D, Suárez-Calvet, M et al. Sci Rep 2019
    PMID:31127154

  8. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Lleó, A, Alcolea, D, Martínez-Lage, P et al. Alzheimers Dement 2019
    PMID:30967340

  9. Nanoscale structure of amyloid-β plaques in Alzheimer's disease. Querol-Vilaseca, M, Colom-Cadena, M, Pegueroles, J et al. Sci Rep 2019
    PMID:30914681

  10. The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk. Belbin, O, Morgan, K, Medway, C et al. J. Alzheimers Dis. 2019
    PMID:30909233

  11. Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Brain 2019
    PMID:30906945

  12. Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. Lleó, A, Parnetti, L, Belbin, O et al. Clin. Chim. Acta 2019
    PMID:30682327

  13. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Lleó, A, Núñez-Llaves, R, Alcolea, D et al. Mol. Cell Proteomics 2019
    PMID:30606734

  14. Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Delaby, C, Muñoz, L, Torres, S et al. Clin. Chim. Acta 2019
    PMID:30579960

  15. Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Pegueroles, J, Jiménez, A, Vilaplana, E et al. Oncotarget 2018
    PMID:30410669

  16. Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. Giménez, S, Videla, L, Romero, S et al. J Clin Sleep Med 2018
    PMID:30353801

  17. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Alcolea, D, Irwin, DJ, Illán-Gala, I et al. J. Neurol. Neurosurg. Psychiatry 2019
    PMID:30297518

  18. CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum. Illán-Gala, I, Alcolea, D, Montal, V et al. Neurology 2018
    PMID:30291183

  19. Challenges associated with biomarker-based classification systems for Alzheimer's disease. Illán-Gala, I, Pegueroles, J, Montal, V et al. Alzheimers Dement (Amst) 2018
    PMID:30175226

  20. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Fortea, J, Carmona-Iragui, M, Benejam, B et al. Lancet Neurol 2018
    PMID:30172624

  21. Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents. Blesa, R, Toriyama, K, Ueda, K et al. Curr Alzheimer Res 2018
    PMID:29895249

  22. Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Morenas-Rodríguez, E, Sala, I, Subirana, A et al. J. Alzheimers Dis. 2018
    PMID:29889064

  23. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. Lleó, A, Irwin, DJ, Illán-Gala, I et al. JAMA Neurol 2018
    PMID:29554190

  24. Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Cantero, JL, Atienza, M, Sanchez-Juan, P et al. Neurobiol. Aging 2018
    PMID:29331877

  25. Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Jimenez, A, Pegueroles, J, Carmona-Iragui, M et al. Oncotarget 2017
    PMID:29285207

Llista completa